Validation of RCC Predicting Model With Emulated-target Trial

Recruiting now

Conditions studied: Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Tumor Thrombus, Prognosis, Prognostic Cancer Model, Real World Study, Observational Study

In brief

This single-center study utilizes real-world data (2012-2024) from 4700 renal cell carcinoma (RCC) patients at Peking University Third Hospital to: (1) Develop and validate a prognostic prediction model specifically for RCC patients, including those with venous tumor thrombus (VTT); (2) Compare the performance of this new model against existing RCC prediction models in both the overall RCC cohort and the VTT subgroup; (3) Employ an emulated target trial (ETT) methodology to evaluate whether risk-stratified treatment based on the prediction model (grouping patients as high/medium/low risk) improves survival outcomes .

Key facts

Study ID

NCT07117227

Run by

Peking University Third Hospital

People needed

4700

Starts

2025-09-01

Expected to finish

2027-08-01

Last updated by the study team

2026-04-14

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults ≥18 years of age;
• Diagnosis of primary renal cell carcinoma before and during the surgery;
• Received radical nephrectomy/nephron-sparing surgery.

You may not qualify if…

• Subjects with severely missing clinical information;
• History of other malignant tumors.
• Recurrence observed before first postoperative follow-up.
• Discontinue the adjuvant treatment within in the first two course because of severe adverse react.

Where it is running

• Peking University Third Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.